A House of Lords committee has urged the UK government to address the regulatory and supply problems caused by the Northern Ireland Protocol, including the potential for regulatory divergence between Great Britain and the EU, the need for different medicine packs for Great Britain and Northern Ireland, and whether medicines should be removed from the scope of the protocol altogether.
EU legislation introduced in 2022 removed the immediate threat of large-scale withdrawals of medicines in Northern Ireland, but drug supply remains “logistically complex, costly and inefficient,” according to the Lords’ European Affairs Sub-Committee on the Protocol on Ireland/Northern Ireland